Table 12.

Reduction in 10-year risk of major CVD endpoints (CHD death/non-fatal MI) in major statin trials, or sub-studies of major trials, in diabetic subjects (N = 16,032)

Study (ref.)	CVD prevention	Statin dose and comparator	Risk reduction	Relative risk reduction	Absolute risk reduction	LDL cholesterol reduction (%)
4S-DM (211)	2°	Simvastatin 20–40 mg vs. placebo	85.7 to 43.2%	50%	42.5%	186 to 119 mg/dl (36%)
ASPEN 2° (216)	2°	Atorvastatin 10 mg vs. placebo	39.5 to 24.5%	34%	12.7%	112 to 79 mg/dl (29%)
HPS-DM (212)	2°	Simvastatin 40 mg vs. placebo	43.8 to 36.3%	17%	7.5%	123 to 84 mg/dl (31%)
CARE-DM (213)	2°	Pravastatin 40 mg vs. placebo	40.8 to 35.4%	13%	5.4%	136 to 99 mg/dl (27%)
TNT-DM (214)	2°	Atorvastatin 80 mg vs. 10 mg	26.3 to 21.6%	18%	4.7%	99 to 77 mg/dl (22%)
HPS-DM (212)	1°	Simvastatin 40 mg vs. placebo	17.5 to 11.5%	34%	6.0%	124 to 86 mg/dl (31%)
CARDS (234)	1°	Atorvastatin 10 mg vs. placebo	11.5 to 7.5%	35%	4.0%	118 to 71 mg/dl (40%)
ASPEN 1° (216)	1°	Atorvastatin 10 mg vs. placebo	9.8 to 7.9%	19%	1.9%	114 to 80 mg/dl (30%)
ASCOT-DM (215)	1°	Atorvastatin 10 mg vs. placebo	11.1 to 10.2%	8%	0.9%	125 to 82 mg/dl (34%)

Studies were of differing lengths (3.3–5.4 years) and used somewhat different outcomes, but all reported rates of CVD death and non-fatal MI. In this tabulation, results of the statin on 10-year risk of major CVD endpoints (CHD death/non-fatal MI) are listed for comparison between studies. Correlation between 10-year CVD risk of the control group and the absolute risk reduction with statin therapy is highly significant (P = 0.0007). Analyses provided by Craig Williams, PharmD, Oregon Health & Science University, 2007.